Safety and efficacy in pediatric patients with relapsed/refractory classic Hodgkin lymphoma enrolled on an intergroup randomized phase II study of the combinations of ipilimumab, nivolumab and brentuximab vedotin (E4412) Meeting Abstract
| Authors: | Forlenza, C. J.; Jegede, O.; Ansell, S. M.; Steidl, C.; Natkunam, Y.; Scott, D. W.; Mehta-Shah, N.; Amengual, J. E.; Cole, P. D.; Kahl, B. S.; Diefenbach, C. S. |
| Abstract Title: | Safety and efficacy in pediatric patients with relapsed/refractory classic Hodgkin lymphoma enrolled on an intergroup randomized phase II study of the combinations of ipilimumab, nivolumab and brentuximab vedotin (E4412) |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 4427 |
| Language: | English |
| ACCESSION: | WOS:001410587900012 |
| DOI: | 10.1182/blood-2024-201624 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
